ClinicalTrials.gg
CompletedNCT01177956CHANGEUpdated Sep 3, 2014Results posted

A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck

A Phase 3 interventional study of Cetuximab and Cisplatin in Squamous Cell Carcinoma of the Head and Neck, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-03.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
73
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck — 11 open to participants now, 19 under way, 7 of them phase 3. Cetuximab · Squamous Cell Carcinoma of Head and Neck.

Enrollment
25th of 84
73 · median 46
Started
2009
with 8 others
Phase 3
16 of 86
4 open now
Registered
33rd of 86
by date
Lead sponsor
4 of 86
Merck KGaA, Darmstadt, Germany

Among the 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck, this one is the 25th largest by enrollment of the 84 interventional ones that give a count, is one of 9 that started in 2009, is one of 16 in phase 3, and was the 33rd registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

11 of the 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck are open now, in 4 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

The primary objective of this trial is to assess the antitumor activity and safety profile of cetuximab when given in combination with cisplatin + 5-Fluorouracil (5-FU) for the first-line treatment of recurrent and/or metastatic Squamous Cell Carcinoma in Head and Neck (SCCHN) in Asian subjects.

03

Conditions studied

  • Squamous Cell Carcinoma of the Head and Neck

Keywords

  • Recurrent and/or metastatic squamous cell carcinoma of the head and neck
  • 1st-line
  • Cetuximab
  • Chemotherapy
  • EMR 62241 -055
  • Merck KGaA
  • Recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written
  • Inpatient
  • Greater than or equal to (>=) 18 years of age
  • or cytologically confirmed diagnosis of SCCHN
  • Recurrent and/or SCCHN not suitable for local therapy
  • Presence of at least 1 identified either by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to modified WHO criteria
  • performance status (KPS) >= 80 percent at trial entry
  • Neutrophils >= 1.5*10\^9 per liter (L), count >= 100*10\^9 per L, and >= 90 gram per liter (g/L)
  • Total less than or equal to (\<=) 2* (ULN); (AST) and alanine aminotransferase (ALT) \<=3*ULN
  • Serum creatinine \<=133 micromole per liter (mcmol/L)
  • Serum calcium within normal range
  • Effective if procreative potential exists (applicable for both male and female subjects)

Exclusion criteria

Exclusion Criteria:

  • Prior systemic chemotherapy, except if given as part of a multimodal treatment which was completed more than 6 months prior to trial entry
  • Surgery (excluding prior diagnostic ) or irradiation within 4 weeks before trial entry
  • Nasopharyngeal carcinoma
  • Active infection (infection requiring IV antibiotics), including active tuberculosis, or known and declared (HIV)
  • Uncontrolled diabetes mellitus, pulmonary fibrosis, acute pulmonary disorder, interstitial pneumonia, cardiac failure or liver failure
  • Uncontrolled hypertension defined as systolic blood pressure >=180 millimeter of mercury (mmHg) and/or diastolic blood pressure >=130 mmHg under resting conditions
  • Pregnancy (absence to be confirmed by serum beta human chorionic gonadotrophin [beta-HCG] test) or breastfeeding
  • Concomitant chronic systemic immune therapy or hormonal therapy as cancer therapy
  • Other concomitant anticancer therapies
  • Documented or symptomatic brain or
  • coronary artery disease or history of myocardial infarction in the last 12 months or high risk of uncontrolled arrhythmia or uncontrolled cardiac insufficiency
  • Medical or psychological condition that would not permit the subject to complete the trial or sign
  • Known drug abuse (with the exception of alcohol abuse)
  • Known or allergic reaction against any of the components of the trial treatment
  • Previous treatment with monoclonal antibody therapy, other signal transduction inhibitors or epidermal growth factor receptor (EGFR) targeting therapy
  • Previous or current other squamous cell carcinoma (SCC)
  • Evidence of previous other within the last 5 years
  • Signs and symptoms suggestive of transmissible spongiform encephalopathy, or family members who suffer(ed) from such
  • Intake of any medication within 30 days before trial entry
  • Legal incapacity or limited legal capacity
  • Other significant disease that in the Investigator's opinion would exclude the subject from the trial
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Cetuximab + Cisplatin + 5-Fluorouracil (5-FU)

    Biological: Cetuximab · Drug: Cisplatin · Drug: 5-Fluorouracil

Interventions

  • BiologicalCetuximab

    The initial dose of cetuximab will be 400 milligram per square meter (mg/m\^2) as an intravenous (IV) infusion over 120 minutes. Subsequent weekly doses will be 250 mg/m\^2 as an IV infusion over 60 minutes. Chemotherapy will be continued for up to a maximum of six 3-week cycles in the absence of progressive disease (PD) or unacceptable toxicity. All subjects will receive cetuximab treatment until the occurrence of PD or unacceptable toxicity to cetuximab.

    Also known as: Erbitux®

  • Subjects will receive 75 mg/m\^2 cisplatin as an IV infusion over 60 minutes on day 1 of each 3-week treatment cycle.

  • Subjects will receive 750 mg/m\^2 per day 5-FU as a continuous IV infusion over 24 hours from day 1 to day 5 of each 3-week treatment cycle.

06

What researchers measure

Primary outcomes

  1. Best Overall Response (BOR) Until Cut-off Date 25 January 2011

    BOR: Percentage of participants experiencing a Complete Response (CR) (complete disappearance of measurable and evaluable disease without new lesions) or Partial Response (PR) (greater than or equal to 50 percent decrease of sum of product diameters of measurable disease, evaluable disease not worsening or progressing, no new lesions confirmed by a subsequent assessment no less than 28 days after criteria for response were first met) (based on modified World Health Organization \[WHO\] criteria), divided by the number of participants belonging to intention to treat (ITT) or safety population.

    Time frame: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 25 January 2011

  2. Best Overall Response (BOR) Until Cut-off Date 15 November 2012

    BOR: Percentage of participants experiencing a CR (complete disappearance of measurable and evaluable disease without new lesions) or PR (greater than or equal to 50 percent decrease of sum of product diameters of measurable disease, evaluable disease not worsening or progressing, no new lesions confirmed by a subsequent assessment no less than 28 days after criteria for response were first met) (based on modified WHO criteria), divided by the number of participants belonging to ITT or safety population.

    Time frame: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 15 November 2012

Secondary outcomes

  1. Overall Survival (OS) Time Until Cut-off Date 15 November 2012

    The OS time was defined as the time from first administration of trial treatment to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.

    Time frame: Time from randomization to death or last day known to be alive, reported between day of first participant randomized, 25 December 2009, until cut-off date 15 November 2012

  2. Progression-free Survival (PFS) Time Until Cut-off Date 25 January 2011

    Duration from first administration of trial treatment until progression (radiological or clinical, if radiological progression is not available) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Participants without event are censored on the date of last tumor assessment.

    Time frame: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 25 January 2011

  3. Progression-free Survival (PFS) Time Until Cut-off Date 15 November 2012

    Duration from first administration of trial treatment until progression (radiological or clinical, if radiological progression is not available) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Participants without event are censored on the date of last tumor assessment.

    Time frame: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 15 November 2012

  4. Time to Progression (TTP) Until Cut-off Date 25 January 2011

    Time from first administration of trial treatment to disease progression (radiological or clinical, if radiological progression is not available). Participants without event are censored on the date of last tumor assessment.

    Time frame: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 25 January 2011

  5. Time to Progression (TTP) Until Cut-off Date 15 November 2012

    Time from first administration of trial treatment to disease progression (radiological or clinical, if radiological progression is not available). Participants without event are censored on the date of last tumor assessment.

    Time frame: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 15 November 2012

  6. Duration of Response Until Cut-off Date 25 January 2011

    Time from first assessment of CR or PR to disease progression or death (within 60 days of last tumor assessment). Participants without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria.

    Time frame: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 25 January 2011

  7. Duration of Response Until Cut-off Date 15 November 2012

    Time from first assessment of CR or PR to disease progression or death (within 60 days of last tumor assessment). Participants without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria.

    Time frame: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 15 November 2012

07

Results

Posted Aug 10, 2012

Participant flow

First/last participant (informed consent): December 2009/September 2010. Clinical data cut-off: 25 January 2011, Study completion date: November 2012

Participant flow — Overall Study
MilestoneCetuximab + Cisplatin + 5-FU
Started68
Completed68
Not completed0

Outcome measures

PrimaryBest Overall Response (BOR) Until Cut-off Date 25 January 2011

BOR: Percentage of participants experiencing a Complete Response (CR) (complete disappearance of measurable and evaluable disease without new lesions) or Partial Response (PR) (greater than or equal to 50 percent decrease of sum of product diameters of measurable disease, evaluable disease not worsening or progressing, no new lesions confirmed by a subsequent assessment no less than 28 days after criteria for response were first met) (based on modified World Health Organization \[WHO\] criteria), divided by the number of participants belonging to intention to treat (ITT) or safety population.

Time frame:
Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 25 January 2011
Reported as:
Number · percentage of participants
Best Overall Response (BOR) Until Cut-off Date 25 January 2011
percentage of participantsCetuximab + Cisplatin + 5-FU
Best Overall Response (BOR) Until Cut-off Date 25 January 201154.4 (41.9 to 66.5)
SecondaryOverall Survival (OS) Time Until Cut-off Date 15 November 2012

The OS time was defined as the time from first administration of trial treatment to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.

Time frame:
Time from randomization to death or last day known to be alive, reported between day of first participant randomized, 25 December 2009, until cut-off date 15 November 2012
Reported as:
Median · months
Overall Survival (OS) Time Until Cut-off Date 15 November 2012
monthsCetuximab + Cisplatin + 5-FU
Overall Survival (OS) Time Until Cut-off Date 15 November 201212.6 (9.1 to 15.0)
SecondaryProgression-free Survival (PFS) Time Until Cut-off Date 25 January 2011

Duration from first administration of trial treatment until progression (radiological or clinical, if radiological progression is not available) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Participants without event are censored on the date of last tumor assessment.

Time frame:
Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 25 January 2011
Reported as:
Median · months
Progression-free Survival (PFS) Time Until Cut-off Date 25 January 2011
monthsCetuximab + Cisplatin + 5-FU
Progression-free Survival (PFS) Time Until Cut-off Date 25 January 20116.2 (5.1 to 8.1)
SecondaryProgression-free Survival (PFS) Time Until Cut-off Date 15 November 2012

Duration from first administration of trial treatment until progression (radiological or clinical, if radiological progression is not available) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Participants without event are censored on the date of last tumor assessment.

Time frame:
Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 15 November 2012
Reported as:
Median · months
Progression-free Survival (PFS) Time Until Cut-off Date 15 November 2012
monthsCetuximab + Cisplatin + 5-FU
Progression-free Survival (PFS) Time Until Cut-off Date 15 November 20126.6 (5.1 to 7.7)
SecondaryTime to Progression (TTP) Until Cut-off Date 25 January 2011

Time from first administration of trial treatment to disease progression (radiological or clinical, if radiological progression is not available). Participants without event are censored on the date of last tumor assessment.

Time frame:
Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 25 January 2011
Reported as:
Median · months
Time to Progression (TTP) Until Cut-off Date 25 January 2011
monthsCetuximab + Cisplatin + 5-FU
Time to Progression (TTP) Until Cut-off Date 25 January 20116.8 (5.3 to 8.1)
PrimaryBest Overall Response (BOR) Until Cut-off Date 15 November 2012

BOR: Percentage of participants experiencing a CR (complete disappearance of measurable and evaluable disease without new lesions) or PR (greater than or equal to 50 percent decrease of sum of product diameters of measurable disease, evaluable disease not worsening or progressing, no new lesions confirmed by a subsequent assessment no less than 28 days after criteria for response were first met) (based on modified WHO criteria), divided by the number of participants belonging to ITT or safety population.

Time frame:
Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 15 November 2012
Reported as:
Number · percentage of participants
Best Overall Response (BOR) Until Cut-off Date 15 November 2012
percentage of participantsCetuximab + Cisplatin + 5-FU
Best Overall Response (BOR) Until Cut-off Date 15 November 201255.9 (43.3 to 67.9)
SecondaryTime to Progression (TTP) Until Cut-off Date 15 November 2012

Time from first administration of trial treatment to disease progression (radiological or clinical, if radiological progression is not available). Participants without event are censored on the date of last tumor assessment.

Time frame:
Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 15 November 2012
Reported as:
Median · months
Time to Progression (TTP) Until Cut-off Date 15 November 2012
monthsCetuximab + Cisplatin + 5-FU
Time to Progression (TTP) Until Cut-off Date 15 November 20127.0 (5.6 to 8.1)
SecondaryDuration of Response Until Cut-off Date 25 January 2011

Time from first assessment of CR or PR to disease progression or death (within 60 days of last tumor assessment). Participants without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria.

Time frame:
Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 25 January 2011
Reported as:
Median · months
Duration of Response Until Cut-off Date 25 January 2011
monthsCetuximab + Cisplatin + 5-FU
Duration of Response Until Cut-off Date 25 January 20115.7 (4.2 to 9.1)
SecondaryDuration of Response Until Cut-off Date 15 November 2012

Time from first assessment of CR or PR to disease progression or death (within 60 days of last tumor assessment). Participants without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria.

Time frame:
Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 15 November 2012
Reported as:
Median · months
Duration of Response Until Cut-off Date 15 November 2012
monthsCetuximab + Cisplatin + 5-FU
Duration of Response Until Cut-off Date 15 November 20126.1 (5.4 to 7.8)

Adverse events

Collected over Baseline until 30 days after last trial treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cetuximab + Cisplatin + 5-FU : Treatment Emergent Phase—13/68 (19.1%)67/68 (98.5%)
Cetuximab + Cisplatin + 5-FU : Late Phase—0/32 (0%)0/32 (0%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventCetuximab + Cisplatin + 5-FU : Treatment Emergent PhaseCetuximab + Cisplatin + 5-FU : Late Phase
Anaphylactic reactionImmune system disorders2/680/32
Microcytic anemiaBlood and lymphatic system disorders1/680/32
Myocardial infarctionCardiac disorders1/680/32
Mouth hemorrhageGastrointestinal disorders1/680/32
PyrexiaGeneral disorders1/680/32
PneumoniaInfections and infestations1/680/32
Staphylococcal skin infectionInfections and infestations1/680/32
Electrolyte imbalanceMetabolism and nutrition disorders1/680/32
HypomagnesaemiaMetabolism and nutrition disorders1/680/32
Tumor hemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/680/32
Most frequent other events
Showing 10 of 38
Most frequent other events
EventCetuximab + Cisplatin + 5-FU : Treatment Emergent PhaseCetuximab + Cisplatin + 5-FU : Late Phase
LeucopeniaBlood and lymphatic system disorders29/680/32
Weight DecreasedInvestigations29/680/32
NauseaGastrointestinal disorders27/680/32
RashSkin and subcutaneous tissue disorders24/680/32
HypomagnesaemiaMetabolism and nutrition disorders23/680/32
HypokalemiaMetabolism and nutrition disorders22/680/32
ConstipationGastrointestinal disorders21/680/32
NeutropeniaBlood and lymphatic system disorders19/680/32
VomitingGastrointestinal disorders19/680/32
Decreased AppetiteMetabolism and nutrition disorders18/680/32

Baseline characteristics

Intention to treat (ITT) population included all participants who received at least one dose of the investigational medicinal product (IMP) cetuximab or chemotherapy.

Age, Continuous
Age, Continuous(years)Cetuximab + Cisplatin + 5-FU
Mean55.7 ± 9.5
Age, Customized
Age, Customized(participants)Cetuximab + Cisplatin + 5-FU
<65 years55
>=65 years13
Sex: Female, Male
Sex: Female, Male(Participants)Cetuximab + Cisplatin + 5-FU
Female19
Male49
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Cetuximab + Cisplatin + 5-FU
Asian (Chinese)63
Asian (Korean)5
08

Study locations

14 sites
  • Cancer Institute & Hospital, Chinese Academy of Medical Sciences
    Beijing, China
  • Jilin Cancer Hospital
    Changchun, China
  • The Xiangya 2nd Hospital of Central South University
    Changsha City, China
  • Fuijan Provincial Tumor Hospital
    Fuijian, China
  • Nanfang Hospital of Nanfang Medical University
    Guangzhou, China
  • Sun Yat-Sen Univesity Cancer Center
    Guangzhou, China
  • Zhejiang Provincial Tumor Hospital
    Hangzhou, China
  • Jiangsu Cancer Hospital
    Jiangsu, Nanjing, China
  • Tumor Hospital of Guangxi Zhuang Autonomous Region / The Tumor Affiliated Hospital of Guangxi Medical University
    Nanning City, China
  • Eye & ENT Hospital of Fundan University
    Shanghai, China
  • Fundan University Shanghai Cancer Center
    Shanghai, China
  • Tongji Hospital of Tongji Medical College of Huazhong University of Science & Technology
    Wuhan City, China
  • Xijing Hospital, the Fourth Military Medical University
    Xi'an, China
  • Clinical Trial Center of Medical Research Institute, Pusan National University Hospital
    Busan, Korea, Republic of
09

References and documents

Publications

  • Guo Y, Shi M, Yang A, Feng J, Zhu X, Choi YJ, Hu G, Pan J, Hu C, Luo R, Zhang Y, Zhou L, Cheng Y, Lupfert C, Cai J, Shi Y. Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial. Head Neck. 2015 Aug;37(8):1081-7. doi: 10.1002/hed.23707. Epub 2014 Sep 17. PubMed 24710768 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Jan 2011 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2010
First posted
Aug 9, 2010
Start
Dec 2009
Primary completionActual
Jan 2011
CompletionActual
Nov 2012
Results first posted
Aug 10, 2012
Last update
Sep 3, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01177956
Responsible party
Sponsor
First posted
Aug 9, 2010
Start date
Dec 2009
Primary completion
Jan 2011
Completion
Nov 2012
Results posted
Aug 10, 2012
Last update
Sep 3, 2014

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cetuximab · Cisplatin · Fluorouracil

Start the discussion